Search PubMed⌕ Search

PubMed · 8992621

[Reactive thrombocytosis, a lipid dysfunction?].

Abstract

Reactive thrombocytosis (RT, platelet counts > 400 x 10(3)/mm3) following coronary artery bypass grafting (CABG) has previously been reported to occur frequently (20%) and is associated with thrombotic complications, e.g. vein graft occlusion. This prospective study was undertaken in an attempt to identify the underlying causes of RT following CABG. 40 consecutive patients undergoing elective CABG entered the study between December 1 1994 and April 15 1995. Patient characteristics, operation data, cardiopulmonary data and postoperative complications (30 parameters) were evaluated together with routine blood chemistry, hematology, hemostasis and anti-inflammatory parameters (25 parameters/ day, preoperatively until the 9th postoperative day). 15 patients developed RT and 25 served as controls. Patient characteristics did not differ. Operation data, cardiopulmonary bypass data and post-operative complications revealed no group differences, neither did preoperative laboratory results, except that S-cholesterol was higher in the RT-group (6.2 +/- 0.9 vs. 5.3 +/- 0.9, p < 0.018). All blood findings were without group differences throughout the entire study period, except platelet counts, platelet size (PWD) and mean platelet volume (MPV), and AT III levels on the 7th postoperative day, which were significantly lower in controls compared to RT. RT patients had a less marked drop in platelet count immediately after cardiopulmonary bypass than non-RT, together with an increased MPV, but without differences in PWD. There was a significantly higher platelet count in the RT group on the 3rd postoperative day, which remained higher throughout the study period. This study has again found RT frequently occurring after CABG (30%). Preoperative S-cholesterol was significantly higher in the RT group, while other parameters did not differ in RT vs. non-RT. It is therefore possible that RT is linked to a lipid dysfunction, and further studies are ongoing.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J T Christenson, P A Gras, A Grosclaude, F Simonet, M Schmuziger. 1996-11-09. [Reactive thrombocytosis, a lipid dysfunction?].. https://pubmed.ncbi.nlm.nih.gov/8992621/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS.

Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) is the precursor of Delta9-tetrahydrocannabinol (Delta9-THC) in hemp plants. During smoking, the non-psychoactive Delta9-THCA-A is converted to Delta9-THC, the main psychoactive component of marihuana and hashish. Although the decarboxylation of Delta9-THCA-A to Delta9-THC was assumed to be complete--which means that no Delta9-THCA-A should be detectable in urine and blood serum of cannabis consumers--we found Delta9-THCA-A in the urine and blood serum samples collected from police controls of drivers suspected for driving under the influence of drugs (DUID). For LC-MS/MS analysis, urine and blood serum samples were prepared by solid-phase extraction. Analysis was performed with a phenylhexyl column using gradient elution with acetonitrile. For detection of Delta9-THCA-A, the mass spectrometer (MS) (SCIEX API 365 triple-quadrupole MS with TurboIonSpray source) was operated in the multiple reaction monitoring (MRM) mode using the following transitions: m/z357 --> 313, m/z357 --> 245 and m/z357 --> 191. Delta9-THCA-A could be detected in the urine and blood serum samples of several cannabis consumers in concentrations of up to 10.8 ng/ml in urine and 14.8 ng/ml in serum. The concentration of Delta9-THCA-A was below the Delta9-THC concentration in most serum samples, resulting in molar ratios of Delta9-THCA-A/Delta9-THC of approximately 5.0-18.6%. Only in one case, where a short elapsed time between the last intake and blood sampling is assumed, the molar ratio was 18.6% in the serum. This indicates differences in elimination kinetics, which need to be investigated in detail.

Blood Chemical Analysis↗